Renal scar formation and kidney function following antibiotic-treated murine pyelonephritis. by Olson, Patrick D. et al.
Thomas Jefferson University
Jefferson Digital Commons
Student Papers Student Materials
11-1-2017
Renal scar formation and kidney function following
antibiotic-treated murine pyelonephritis.
Patrick D. Olson
Washington University School of Medicine
Lisa K. McLellan
Washington University School of Medicine
Alice Liu
Thomas Jefferson University; Washington University School of Medicine, axl129@jefferson.edu
Kelleigh L. Briden
Washington University School of Medicine
Kristin M. Tiemann
Washington University School of Medicine
See next page for additional authors
Let us know how access to this document benefits you
Follow this and additional works at: http://jdc.jefferson.edu/student_papers
Part of the Pediatrics Commons
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas
Jefferson University's Center for Teaching and Learning (CTL). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly
publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and
interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in
Student Papers by an authorized administrator of the Jefferson Digital Commons. For more information, please contact:
JeffersonDigitalCommons@jefferson.edu.
Recommended Citation
Olson, Patrick D.; McLellan, Lisa K.; Liu, Alice; Briden, Kelleigh L.; Tiemann, Kristin M.;
Daugherty, Allyssa L.; Hruska, Keith A.; and Hunstad, David A., "Renal scar formation and kidney
function following antibiotic-treated murine pyelonephritis." (2017). Student Papers. Paper 12.
http://jdc.jefferson.edu/student_papers/12
Authors
Patrick D. Olson, Lisa K. McLellan, Alice Liu, Kelleigh L. Briden, Kristin M. Tiemann, Allyssa L. Daugherty,
Keith A. Hruska, and David A. Hunstad
This article is available at Jefferson Digital Commons: http://jdc.jefferson.edu/student_papers/12
RESOURCE ARTICLE
Renal scar formation and kidney function following
antibiotic-treated murine pyelonephritis
Patrick D. Olson1,2, Lisa K. McLellan2, Alice Liu2,*, Kelleigh L. Briden2, Kristin M. Tiemann2,
Allyssa L. Daugherty2, Keith A. Hruska2,3 and David A. Hunstad2,4,‡
ABSTRACT
We present a new preclinical model to study treatment, resolution and
sequelae of severe ascending pyelonephritis. Urinary tract infection
(UTI), primarily caused by uropathogenic Escherichia coli (UPEC), is
a common disease in children. Severe pyelonephritis is the primary
cause of acquired renal scarring in childhood, which may eventually
lead to hypertension and chronic kidney disease in a small but
important fraction of patients. Preclinical modeling of UTI utilizes
almost exclusively females, which (in most mouse strains) exhibit
inherent resistance to severe ascending kidney infection;
consequently, no existing preclinical model has assessed the
consequences of recovery from pyelonephritis following antibiotic
treatment. We recently published a novel mini-surgical bladder
inoculation technique, with which male C3H/HeN mice develop
robust ascending pyelonephritis, highly prevalent renal abscesses
and evidence of fibrosis. Here, we devised and optimized an antibiotic
treatment strategy within this male model to more closely reflect the
clinical course of pyelonephritis. A 5-day ceftriaxone regimen initiated
at the onset of abscess development achieved resolution of bladder
and kidney infection. A minority of treated mice displayed persistent
histological abscess at the end of treatment, despite microbiological
cure of pyelonephritis; a matching fraction of mice 1 month later
exhibited renal scars featuring fibrosis and ongoing inflammatory
infiltrates. Successful antibiotic treatment preserved renal function in
almost all infected mice, as assessed by biochemical markers 1 and
5 months post-treatment; hydronephrosis was observed as a late
effect of treated pyelonephritis. An occasional mouse developed
chronic kidney disease, generally reflecting the incidence of this late
sequela in humans. In total, this model offers a platform to study the
molecular pathogenesis of pyelonephritis, response to antibiotic
therapy and emergence of sequelae, including fibrosis and renal
scarring. Future studies in this system may inform adjunctive
therapies that may reduce the long-term complications of this very
common bacterial infection.
KEY WORDS: Pyelonephritis, Renal scarring, Fibrosis, Urinary tract
infection, Chronic kidney disease, Hydronephrosis
INTRODUCTION
Urinary tract infection (UTI) is a common affliction across the
human lifespan, regularly affecting infants and young children in
the first years of life (Foxman, 2003, 2010; Foxman and Brown,
2003; Arshad and Seed, 2015). Ascension of uropathogens to the
kidneys can lead to pyelonephritis, which, even with successful
antibiotic treatment, may carry long-term repercussions for the
patient, including the development of renal scarring, hypertension
and eventual progression to end-stage renal disease (Jacobson et al.,
1989; Martinell et al., 1996; Wennerström et al., 2000; Levey
and Coresh, 2012). Ascending bacterial infection of the renal
parenchyma in humans elicits severe tubulointerstitial inflammation
(Goluszko et al., 1997; Svensson et al., 2005, 2011; Mak and Kuo,
2006; Olson et al., 2016; Li et al., 2017). This innate inflammatory
response, perhaps as much as bacterial processes per se, may largely
underlie renal damage resulting from UTI, and is correlated with
loss of functional renal tissue (scarring) and the development of
fibrosis (Miller and Phillips, 1981; Bille and Glauser, 1982; Anders
and Schaefer, 2014; Suárez-Álvarez et al., 2016). However, whether
pyelonephritic scars contribute to chronic kidney disease (CKD)
and the mechanisms involved are unknown (Salo et al., 2011;
Toffolo et al., 2012; Nevéus, 2013). Furthermore, it is unclear
whether the location, severity or timing of renal fibrosis influences
progression to CKD.
An understanding of the link between infection-related fibrosis
and subsequent development of CKD has been hindered largely by
the lack of robust murine models of ascending severe upper-tract
UTI in immunocompetent hosts (Hopkins et al., 1998; Svensson
et al., 2005, 2011; Hannan et al., 2010). Although cystitis can be
induced by transurethral catheterization in females of many mouse
strains, most are resistant to severe pyelonephritis with abscess
formation after bladder inoculation (Hopkins et al., 1998; Hannan
et al., 2010; Tittel et al., 2011; Hains et al., 2014; Schwartz et al.,
2015; Olson et al., 2016). Several previous studies have utilized
direct injection of uropathogens into the kidneys (Miller and
Phillips, 1981; Santos et al., 1994; Mussalli et al., 1999), but these
models bypass ascension of the ureter and clearly do not recapitulate
natural arrival of uropathogenic Escherichia coli (UPEC) in the
collecting system. Other reports have induced female murine
pyelonephritis with serial, high-colony-forming-unit (CFU)
transurethral inoculations, but did not note gross abscess or severe
nephropathy (Tittel et al., 2011; Bowen et al., 2013; Hains et al.,
2014; Schwartz et al., 2015). Substantial recent work has been
performed in C3H/HeN mice, which are recognized to feature
vesicoureteral reflux (Hopkins et al., 1998; Bowen et al., 2013),
reflecting a primary risk factor for upper-tract UTI in children (Feld
and Mattoo, 2010; Hoberman et al., 2014). In the C3H/HeN mouseReceived 18 April 2017; Accepted 4 September 2017
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strain, a minority of females (the sex historically used almost
exclusively in preclinical UTI work because the bladders of male
mice cannot reliably be accessed by catheter) develop
pyelonephritis – without abscess formation – following bladder
inoculation with UPEC, whereas most females resolve infection
(Hannan et al., 2010). We previously found, using a novel mini-
surgical bladder inoculation technique, that male C3H/HeN mice,
unlike females, develop nearly 100% penetrant severe
pyelonephritis and renal abscesses following ascending infection,
and fail to spontaneously resolve UTI (Olson et al., 2016).
Furthermore, infected males exhibit fibrosis and progressive renal
disease during later stages of infection (Olson et al., 2016).
In addition, prior studies have examined the generation of
inflammation and fibrosis only during untreated, active infection
(Svensson et al., 2005, 2011; Bahat Özdoğan et al., 2014; Olson
et al., 2016; Li et al., 2017), whereas human patients with
pyelonephritis typically would receive antibiotic treatment, such
as a cephalosporin or fluoroquinolone, upon recognition of
symptoms and appropriate laboratory testing (Warren et al., 1999;
Gupta et al., 2011). Thus, we here extended our new preclinical
model of UTI in C3H/HeN males to test the efficacy of antibiotic
treatment in severe pyelonephritis and in early or established renal
abscesses, and to examine long-term sequelae of infection
following antimicrobial treatment.
RESULTS
Ceftriaxone achieves microbiological cure of pyelonephritis
in C3H/HeN males
There exist no optimal preclinical models of antibiotic-treated
severe pyelonephritis and the immediate or long-term detrimental
sequelae of disease. Therefore, we employed mini-surgical
inoculation of the bladders of male C3H/HeN mice to model the
resolution and sequelae of severe pyelonephritis. By 14 days post-
infection (dpi) with UPEC strain UTI89, over 90% of surgically
infected C3H/HeN males develop grossly evident, bilateral renal
abscess (Olson et al., 2016). In our efforts to model antibiotic
treatment, we first attempted multiple ceftriaxone (CRO) dosing
schemes starting 14 dpi in male C3H/HeN mice; these strategies
failed to effectively treat the advanced abscesses established in
kidneys by that time point (Fig. S1). Furthermore, we felt it likely
that patients would more commonly present earlier in the course of
pyelonephritis. In C3H/HeN males, abscesses rapidly become
evident between 5 and 6 dpi, and are fully formed in nearly 100% of
males by 7 dpi (Olson et al., 2016; P.D.O., L.K.M. and D.A.H.,
unpublished data). Therefore, we next elected to initiate CRO or
placebo [phosphate-buffered saline (PBS)] administration [given by
subcutaneous injection every 12 h (q12 h) for 5 days] beginning at
5 dpi, and harvesting organs upon euthanasia 24 h after the final
CRO dose (i.e. 11 dpi; Fig. 1A). Bladder inoculation with UPEC in
male C3H/HeNmice resulted in robust bladder (Fig. 1B) and kidney
(Fig. 1C) infection in both start-of-treatment controls (5 dpi) and
mock-treated animals. CRO treatment significantly reduced bladder
(Fig. 1B; P<0.0001) and kidney (Fig. 1C; P<0.0001) bacterial
burdens compared to mock-treated animals. CRO-treated mice
continued to harbor 102-104 colony-forming units (CFU) of UPEC
in their bladders (Fig. 1B), despite resolving bacteriuria (Fig. 1D);
this finding is consistent with prior reports of UPEC reservoirs
persisting within bladder tissue following antibiotic treatment
(Mysorekar and Hultgren, 2006; Hannan et al., 2010; Blango et al.,
2014; Olson et al., 2016). The majority of CRO-treated mice
completely resolved kidney infection (Fig. 1C). Trials of other
treatment regimens beginning at 5 dpi, including increased CRO
duration, dose or frequency, did not further affect organ bacterial
burdens (Fig. S2) compared to the 5-day q12 h regimen.
CRO treatment beginning at 5 dpi sterilizes existing
abscesses and halts further abscess formation
Among mice sacrificed at the start of treatment (5 dpi), all of which
had high kidney bacterial burdens (Fig. 1B), a minority (4 of 15;
27%) demonstrated grossly and microscopically evident abscess
formation (Fig. 2A), matching our previous report at the same time
point (Olson et al., 2016). By 11 dpi (24 h post-treatment-
completion), all (10 of 10) UPEC-infected, mock-treated males
displayed gross renal abscess formation (Fig. 2B). Thus, abscess
development was progressive during this 6-day interval in the
Fig. 1. CRO treatment eliminates renal bacterial burden in C3H/HeN mice
with pyelonephritis. (A) Male C3H/HeN mice were surgically infected with
UTI89 or PBS and then treated with CRO or PBS for 5 days starting at 5 dpi.
Bladders (B) or kidneys (C) were aseptically homogenized and plated to
enumerate CFU 24 h after the last CRO injection. Organ titers in 5-dpi start-of-
treatment controls (triangles) were equivalent to mock-treated mice at 11 dpi
(black circles), whereas CRO treatment (white circles) significantly reduced
bladder bacterial loads and sterilized the infected kidneys. Mock-infected mice
(diamonds), as expected, bore no bacteria in bladders or kidneys. Data shown
reflect the aggregate of three independent experiments (total n=7-15 per
condition; ***P<0.001 by Mann–Whitney U-test). Dashed lines in all panels
represent the limit of detection; bars indicate the geometric mean. (D) Male
C3H/HeN mice were surgically infected with UTI89, then either mock-treated
(with PBS; black circles) or treated with CRO (gray circles) starting at 5 dpi.
Urine bacterial titers on the indicated days are shown. Solid lines connect
corresponding urine titers from each individual mouse.
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absence of antibiotic treatment. In contrast, the abscess frequency
observed at 11 dpi in CRO-treated mice (4 of 14; 29%; P=0.0006
versus mock-treated; Fig. 2C) was equivalent to 5-dpi start-of-
treatment controls, illustrating that timely antibiotic therapy
interrupted abscess progression. As noted above, these CRO-
treated mice with evident abscess formation exhibited low kidney
bacterial burdens (at or near the lower limit of detection; Fig. 1A)
and did not have ongoing bacteriuria (Fig. 1D). These data suggest
that CRO treatment beginning at 5 dpi arrested renal abscess
development and neutralized the burgeoning UPEC population
within the renal parenchyma. As expected, control mice (mock-
infected with PBS and treated with CRO) displayed healthy kidney
architecture 24 h post-treatment (Fig. 2D).
Convalescent outcomes in treated pyelonephritis
Whereas the majority of CRO-treated mice demonstrated
microbiological cure of pyelonephritis 1 day post-treatment, a few
maintained very low residual UPEC burdens (Fig. 1B,C). It was
unclear whether such UPEC remaining in the bladder or kidney
post-CRO-treatment would reemerge to cause recrudescent
infection. To specify outcomes in treated pyelonephritis, we
treated UPEC-infected mice with CRO or PBS for 5 days,
beginning at 5 dpi, and quantified organ bacterial burdens
4 weeks post-treatment. Mock-treated mice all exhibited high
bladder bacterial burdens (typical of chronic cystitis) and kidney
burdens at this later time point (Fig. 3A), consistent with the near-
complete prevalence of these severe UTI outcomes in C3H/HeN
males that we reported previously (Olson et al., 2016). All CRO-
treated mice resolved renal and bladder infection (Fig. 3A;
P=0.0007 and P=0.0003, respectively, versus mock-treated
controls). No CRO-treated mice displayed urine UPEC titers
>104 CFU ml−1 at biweekly samplings (Fig. S3), but a minority
maintained low-level colonization of the bladder (Fig. 3A), again
consistent with quiescent reservoir formation as previously reported
(Mysorekar and Hultgren, 2006; Hannan et al., 2010; Blango et al.,
2014; Olson et al., 2016). Remarkably, gross renal scars were found
in several CRO-treated mice at necropsy 4 weeks post-treatment
(Fig. 3B, arrowheads). Affected kidneys demonstrated broad-based,
U-shaped cortical scarring with retraction of the renal parenchyma,
matching the pathological descriptions of human pyelonephritic
scars (Smith, 1962; Paueksakon and Fogo, 2014). The fraction of
mice displaying grossly visible renal scars 4 weeks following CRO
treatment (28%) was equivalent to the fraction of mice
demonstrating abscess at either the start of treatment (5 dpi) or
1 day post-treatment (11 dpi) (Fig. 3C). Collectively, these data
indicate that the tissue destruction associated with microscopic
abscess formation is spatially and pathologically associated with the
subsequent development of renal scars.
Renal scars, despite resolution of infection, harbor
progressive inflammation
Histopathological analysis of UPEC-infected CRO-treated kidney
sections by Gomori trichrome staining revealed extensive cortical
scars 4 weeks post-treatment, with collagen deposition in some
scars extending from the renal capsule to the medulla (Fig. 4A). The
strictures we observed on gross inspection of recovered kidneys
(Fig. 3B) were also evident microscopically, and the renal capsule
was substantially thickened overlying the scar (Fig. 4B). Fibrosis in
Fig. 2. CRO treatment reduces prevalence of
renal abscess. (A) A minority (27%) of infected
C3H/HeN males sacrificed before the start of
treatment already exhibited abscess formation at
this time point (representative image among n=15
mice). (B) 100% of UTI89-infected C3H/HeN males
receiving mock treatment (PBS) displayed
abscesses 1 day post-treatment (representative
image among n=10 mice). (C) The prevalence of
abscess in UTI89-infected CRO-treated mice
(29%) matched that prior to treatment, indicating
that CRO treatment prevented further abscess
formation but did not reverse tissue damage
already present in abscessed kidneys, even though
microbiological cure was achieved (representative
image among n=14 mice). (D) Mock-infected CRO-
treated control mice exhibited normal kidney
architecture 1 day after treatment conclusion
(representative image among n=7 mice). Gomori
trichrome staining; scale bar: 200 µm.
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these scars followed patterns similar to those observed at earlier
stages of abscess development at 5 and 11 dpi in infected CRO-
treated mice (see Fig. 2). No scars were observed in mock-infected
CRO-treated animals. More striking was the presence of a cellular
infiltrate within the scar (Fig. 4C,D), despite all tested animals
resolving renal infection (Fig. 3A) and exhibiting sterile urine
cultures. Collections of inflammatory cells (primarily lymphocytes)
and fibroblasts were embedded within the area of fibrosis (Fig. 4D).
These data indicate that the development and maturation of renal
scars is an active process that continues following successful
microbiological cure of infection with antibiotics.
Successful CRO treatment restores renal function
Human patients that develop acute pyelonephritis typically manifest
baseline renal function following resolution of infection; renal scars
and other adverse sequelae of resolved infection are identified in a
minority of patients, and some are not evident clinically until later in
life (Jacobson et al., 1989; Martinell et al., 1996; Wennerström
et al., 2000; Shaikh et al., 2010; Levey and Coresh, 2012). In the
UPEC-infected CRO-treated mice that resolved infection and lacked
evidence of renal scarring 4 weeks post-treatment, histopathological
analysis of Gomori trichrome-stained kidney sections showed no
increase in interstitial fibrosis compared to mock-infected controls,
and normal overall renal architecture similar to mock-infected
animals (Fig. 5A,B). However, we frequently observed areas of
glomerular sclerosis in these UTI89-infected CRO-treated scar-free
animals (Fig. 5B). We also performed serial measurements of blood
urea nitrogen (BUN) as a biochemical marker of renal function in
UPEC-infected mice. These data demonstrate that BUN remained
stable in mice receiving CRO treatment, whereas ongoing infection
(i.e. mock treatment) was associated with an increase in BUN
(Fig. 5C).
Long-term outcomes reflect those observed in human
patients
Children who develop renal scars following UTI may be followed
into adulthood, when signs of CKD may manifest in a minority of
such patients (Jacobson et al., 1989; Martinell et al., 1996;
Wennerström et al., 2000; Levey and Coresh, 2012). Therefore,
we surgically inoculated male C3H/HeN mice with either PBS
(mock) or UTI89, treated with CRO for 5 days beginning at 5 dpi
and then observed these mice until 30 weeks of age (i.e. 5 months
post-treatment). Successful antibiotic treatment preserved normal
renal function in the majority of UPEC-infected mice at this longer
interval; mean serum creatinine (Fig. 6A), BUN (Fig. 6B) and urine
protein (Fig. 6C) were not significantly higher than in mock-infected
mice. However, in one UPEC-infected mouse (Fig. 6) that developed
particularly notable bilateral scars, these three biochemical markers
were markedly higher, indicating the development of CKD.
Surprisingly, we found grossly visible bilateral hydronephrosis in
80% of the UPEC-infected CRO-treated mice allowed to age to
30 weeks. These animals had bilaterally dilated ureters (Fig. 7A),
and expansion of the renal pelvis was visible on bisection of the
kidneys. Histopathology confirmed these findings, with infected
animals displaying enlarged, dilated renal pelvis and calyces,
flattening of the pelvic epithelia, atrophy and thinning of the renal
cortex, and expanded ureters (Fig. 7B). These abnormal features
were uniformly absent in mock-infected CRO-treated animals at
30 weeks of age (Fig. 7C). There was no evidence of
hydronephrosis at 11 or 38 dpi in any mock- or UPEC-infected
mock- or CRO-treated mice (Figs 2, 3, 4). Fibrotic scars in the
parenchyma near the renal pelvis, with persistent inflammatory
infiltrates, were evident microscopically at 30 weeks of age in
UPEC-infected CRO-treated mice (Fig. 7D, as seen at 38 dpi), but
not in mock-infected controls. Histological examination of the
bladders of UPEC-infected CRO-treated mice at this long time point
revealed epithelial changes reflecting bladder remodeling and
chronic inflammatory infiltrates, but no evidence of obstructive
lesions at the ureterovesical junction (Fig. 7E,F).
DISCUSSION
Here, we developed a new model to enable preclinical studies of the
resolution and sequelae of antibiotic-treated upper-tract UTI. To do
so, we leveraged the mini-surgical inoculation technique that allows
infection of C3H/HeNmales, which develop nearly 100% penetrant
severe pyelonephritis and renal abscess following bladder
inoculation with UPEC. Although antibiotic treatment alone was
Fig. 3. Renal scars develop following durably successful CRO treatment.
Male C3H/HeN mice were surgically infected (Inoc) with PBS or UTI89 and
then treated (Treat) with PBS or CRO. (A) Bladders and kidneys were
aseptically harvested, homogenized and CFU enumerated at 38 dpi (28 days
post-treatment). CRO treatment significantly reduced bacterial burden and
resulted in sterile kidney titers at 38 dpi (aggregate of two experiments, total
n=5-8 per condition; **P<0.01, ***P<0.001 by Mann–Whitney U-test). (B)
Following autopsy, gross renal scars were observed in 27% of UPEC-infected
CRO-treated mice at 38 dpi. A representative image of a scarred left kidney is
shown. Arrowheads indicate gross renal scars. (C) The percentage of animals
exhibiting abscesses at 5 dpi (pre-CRO treatment; n=15) or 11 dpi (24 h
following CRO treatment; n=14) is matched by the percentage exhibiting renal
scars at 4 weeks post-CRO-treatment (n=11) (P=not significant by Fisher
exact test for each pairwise comparison).
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not successful when initiated at later time points (presumably
because of very advanced infection, and consistent with clinical
experience in patients with established abscesses), CRO treatment
initiated at 5 dpi achieved resolution of infection, aborting the
abscess development that begins at that time. An appropriate
minority of these infected and successfully treated animals
developed renal scars by 1 month post-treatment; these scars
showed fibrosis and ongoing inflammatory cellular infiltrates. At
longer follow-up, an even smaller proportion demonstrated
biochemical evidence of CKD.
Roughly one third of infected male C3H/HeN mice exhibited
abscess at 5 dpi (at the start of treatment) or demonstrated sterile
abscess post-treatment, and a similar fraction of mice demonstrated
renal scarring 1 month after successful antibiotic treatment. Current
limitations of live-animal imaging preclude a definitive link
between the anatomic locations of initial abscess and ultimate
renal scar. However, we can reasonably posit that abscess
development, with associated renal parenchymal necrosis and
replacement with inflammatory infiltrates, gives way to scar
formation in this spatially identical region of a given kidney.
Following antibiotic treatment, sterile abscesses featured
inflammation and tissue destruction similar to descriptions of
active abscess at 5 dpi (Fig. 2), and inflammation persisted in renal
scars at later time points (Fig. 5), consistent with reports from
human pathology (Bernstein and Arant, 1992). This temporal and
spatial association argues that the immune responses to UPEC
introduction and the inflammatory processes surrounding micro-
and macroabscess formation lay the mechanistic foundation for scar
development. This hypothesis is also supported by recent findings
in the C3H/HeOuJ mouse strain (Li et al., 2017). It follows that, if
these mechanisms can be understood at a molecular level, future
targeted therapeutic modalities may attenuate or alter the nature of
renal inflammation and/or impact the inflammatory modulators
released from pyelonephritic scars (Haraoka et al., 1994; Pohl et al.,
1999; Nevéus, 2013; Bahat Özdoğan et al., 2014), ultimately
reducing risk for CKD.
Our preclinical model of renal scarring following successful
antibiotic treatment of ascending upper-tract UTI fills a substantial
gap in the field and reproduces the outcomes observed in patients,
particularly children, with pyelonephritis. Only a small percentage
of humans presenting with upper-tract UTI develop renal scars
following resolution of acute infection, and it is unclear why some
individuals develop these scars whereas others do not (Hewitson,
2009; Shaikh et al., 2010; Strohmeier et al., 2014). Estimates of the
risk of renal scarring after pyelonephritis in children vary, but range
between 8 and 40%, with a meta-analysis concluding that ∼15% of
such children have demonstrable evidence of scarring at follow up
(Jakobsson et al., 1994; Shaikh et al., 2010). The model described in
the present work approximates this proportion, with 27-29% of mice
developing renal scars. Clinical studies have shown that early and
aggressive antibiotic treatment minimizes the risk of renal scar
formation (Miller and Phillips, 1981; Winter et al., 1983; Shaikh
et al., 2016); our studies reinforce this point, suggesting that minor
delays in the start of antimicrobial treatment could substantially
influence whether permanent renal damage occurs or whether
pyelonephritis instead resolves without complication.
This work was limited to the study of an adult male murine
model, employed to overcome the shortcomings of previous female
Fig. 4. Post-pyelonephritic scars demonstrate
ongoing active inflammation. Gomori trichrome
staining of UPEC-infected mice (n=11) with grossly
evident scars but negative organ bacterial titers
28 days after completion of CRO treatment
demonstrated collagen deposition as well as
replacement and retraction of cortical tissue
(A,B; scale bars: 200 µm). This was accompanied
by dramatic capsular thickening over the scar and a
cellular infiltrate (C, inset from B; scale bar: 50 µm)
that morphologically consisted primarily of
lymphocytes (D; scale bar: 20 µm).
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models of pyelonephritis. The sex ratio in UTI among infants favors
females, but approximates 2:1 over the first 2 years of life. A
number of studies indicate that male cases outnumber female
neonatal UTI within the first 6 months after birth (Winberg et al.,
1974; Ginsburg and McCracken, 1982; Wettergren et al., 1985;
Kanellopoulos et al., 2006; Wong et al., 2010; Ismaili et al., 2011;
Park et al., 2011; Bonadio and Maida, 2014). Furthermore, several
reports suggest that male sex may be a prognostic factor for the
development of renal scarring in infants that develop febrile UTI
(Marra et al., 2004; Soylu et al., 2008; Mattoo et al., 2015). This
matches a growing body of evidence that male sex may be an
indicator for worse morbidity, mortality or sequelae from
pyelonephritis (Nicolle et al., 1996; Efstathiou et al., 2003;
Foxman et al., 2003; Ki et al., 2004; Olson et al., 2016).
Additionally, the clinical data supporting an age-related influence
on risk for scarring after childhood pyelonephritis are variable, but
on balance may indicate a slight predisposition for developing renal
scars in older children presenting with pyelonephritis (Benador
et al., 1997; Ataei et al., 2005; Shaikh et al., 2014). Futurework with
our CRO treatment model in female models of ascending UTI and in
male mice of varying age could further define the influences of sex
and age, respectively, on post-pyelonephritic fibrosis and sequelae
of infection.
Our experiments also reveal translationally appropriate rates of
long-term sequelae, both scarring and CKD. To clearly delineate the
association and mechanistic pathways leading to CKD specifically
in this model, future studies will require substantially larger sample
sizes. Alternatively, the incidence of the CKD outcome might be
augmented by infecting with a greater inoculum or by initiating
treatment somewhat later in infection (e.g. 7 dpi), when a larger
proportion of C3H/HeN males will have established abscesses
(Olson et al., 2016). Most non-infectious murine models of CKD
require some combination of unilateral or subtotal nephrectomy,
ureteral obstruction, and injury or insult to the remaining kidney
(Davies et al., 2003, 2005; Manson et al., 2011; Agapova et al.,
2016); one could imagine attempting to increase the incidence of
post-pyelonephritic CKD by introducing a similar unilateral or
partial nephrectomy procedure prior to UPEC infection and
antibiotic treatment. Measurement of blood pressure will help to
correlate renal scars in mice with hypertension, which is more
common as a sequela of human pyelonephritis than is CKD.
Continued work along these lines will provide further evidence to
define the relationship between pyelonephritic scar formation and
risk for CKD.
Although it is accepted that UTI risk is enhanced in individuals
with hydronephrosis associated with vesicoureteral reflux (VUR) or
urodynamic obstruction (Feld and Mattoo, 2010; Hoberman et al.,
2014), there is, to our knowledge, no conclusive paradigm in which
pyelonephritis and/or severe cystitis causes or reveals the presence
of hydronephrosis. Several early studies did speculate that infection
might cause an increase in VUR, although the evidence for cystitis
either promoting VUR or having no effect on VUR is relatively
weak (Hanley, 1962; Howerton and Lich, 1963; Tanagho et al.,
1965; Gross and Lebowitz, 1981; Garin et al., 1998). The
hydronephrosis we observed in long-term follow-up of infected
and successfully treated C3H/HeN males – mice known to have
preexisting VUR – suggests that incident UTI may worsen such
reflux, either temporarily or in a more protracted way. Future studies
that optimize models of severe pyelonephritis in non-refluxing
backgrounds such as C57BL/6 (Tittel et al., 2011; Hains et al.,
2014) may ascertain the contribution of VUR to the phenotypes we
observed in C3H/HeN males. Other potential causes of bilateral
hydronephrosis in these recovered males, such as bilateral ureteral or
ureterovesical obstruction, were not observed but are not completely
excluded by the present data. Papillary blunting and hydronephrosis
were not seen in UPEC-infected, mock-treated animals, or at earlier
time points immediately following antibiotic treatment, suggesting
Fig. 5. CRO treatment preserves normal short-term renal function.
(A) Gomori trichrome staining of renal cortex illustrates healthy kidney
histology, at 28 days post-treatment, in mock-infected mice treated with CRO
(representative image from n=10 mice). (B) UPEC-infected mice that resolved
pyelonephritis via CRO treatment and lacked gross scars demonstrated minor
glomerular sclerosis, but displayed otherwise normal kidney architecture
(representative image from n=14 mice). Scale bar for A and B: 50 µm.
(C) Blood urea nitrogen (BUN) rose over a 30-day interval in UPEC-infected
mice (n=4-5 per condition) that did not receive antibiotics (*P=0.029 by
Mann–Whitney U-test, 5 days versus 30 days), but remained at baseline in
mice that were treated with CRO (P= not significant by Mann–Whitney U-test,
5 days versus 30 days).
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that these findings may arise in association with long-term
remodeling and fibrosis responses in the bladder, ureter and/or
kidney. In any case, fibrosis is evident much earlier in the course of
recovery than is hydronephrosis; it is therefore unlikely that
hydronephrotic injury is the initiator of fibrosis in this model,
although it may contribute to progression of fibrosis. Other recent
studies have begun to illuminate not only macroscopic, but
microscopic and molecular, imprints left by severe UTI on the
urinary tract and its cellular constituents (O’Brien et al., 2015, 2016;
Schwartz et al., 2015). These studies may support the concept of a
vicious cycle in patients with urodynamic abnormalities, who are
already predisposed to UTI but whose urodynamics may also
regress with repeated UTI.
In summary, we report a novel system for modeling the
complications arising from severe UTI. Susceptible hosts develop
renal abscess upon ascending UPEC infection and, despite successful
antibiotic therapy, a translationally relevant proportion of mice
ultimately develop renal scars after treatment. This model promises to
address the relationships between the development of pyelonephritis,
timing and effectiveness of antibiotic therapy, and sequelae
(including renal scarring and CKD), as well as to illuminate the
soluble and cellular inflammatory components responsible for
ongoing renal damage following microbiological resolution.
MATERIALS AND METHODS
Bacteria
UPEC strain UTI89 was isolated from a patient with cystitis (Chen et al.,
2009). For surgical infections, bacteria were grown statically in Luria-
Bertani (LB) broth for 16 h at 37°C. The cultures were centrifuged for
10 min at 7500 g at 4°C before resuspension in sterile PBS to a final density
of 4×108 CFU ml−1.
Introduction of murine UTI
All animal procedures received prior review and approval from the
Institutional Animal Care and Use Committee at Washington University,
St. Louis, MO, USA. A widely used female murine model of cystitis with
transurethral inoculation via catheter has been described in methodological
detail (Mulvey et al., 1998; Hung et al., 2009; Hannan and Hunstad, 2016),
but this approach is technically precluded in male animals. A recently
developed surgical approach (Olson et al., 2016) was used to initiate
infection in male mice. Eight-week-old male C3H/HeN mice (Envigo,
Indianapolis, IN) were maintained under inhalation anesthesia with 3%
isoflurane via vaporizer and nose cone. Briefly, anesthetized mice were
positioned supine, shaved and the ventral abdomen was sterilized with 2%
chlorhexidine solution. A vertical, midline incision (3 mm in length) was
made directly overlying the bladder, first through the abdominal skin and
then through the peritoneum. The bladder was exposed, aseptically emptied
and punctured with a 30-gauge 0.5-inch needle adapted to a 1-ml tuberculin
syringe containing the bacterial inoculum. Fifty microliters containing
1×107-2×107 CFU was introduced to the bladder lumen over 10 s, the
bladder was allowed to expand for a further 10 s, and the needle was then
withdrawn. The peritoneum and the skin were closed with simple,
interrupted sutures, and the animal was awakened in fresh air.
Fig. 6. Successful CRO treatment preserves long-term renal function in most UPEC-infected mice.Mock-infected mice (PBS; circles) and UPEC-infected
mice (triangles) were treated with CRO for 5 days beginning at 5 dpi and aged to 30 weeks (two to three experiments with total n=10-15 per condition). Serumwas
analyzed for creatinine (SCr; A) and blood urea nitrogen (BUN; B), and urine protein was measured (UPro; C). Most UPEC-infected mice demonstrated normal
serum creatinine, BUN and urine protein at 30 weeks of age (P= not significant by Mann–Whitney U-test for each analyte), although one UPEC-infected mouse
that displayed notable bilateral scars also had marked elevation in these biochemical markers.
Fig. 7. Hydronephrosis is observed 5 months post-successful-treatment.
Male C3H/HeN mice were treated with CRO for 5 days beginning at 5 dpi and
aged to 30 weeks as in Fig. 6. The majority of UPEC-infected CRO-treated
males exhibited grossly visible hydronephrosis with dilated ureters
(A, arrowheads). Histopathology of Gomori trichrome-stained sections
confirmed dilated collecting structures and proximal ureter in UPEC-infected
CRO-treated mice (B; scale bar: 500 µm), whereas mock-infected CRO-
treated mice displayed normal kidney architecture without discernible
hydronephrosis (C; scale bar: 500 µm). As was also noted at 4 weeks post-
treatment, UPEC-infected CRO-treated animals at 30 weeks of age displayed
fibrotic scars and continued active inflammation, despite resolving infection
(D; scale bar: 50 µm). Complete sectioning of the bladders from these animals
(E and F; scale bars: 200 µm) did not reveal evidence of obstruction at the
ureterovesical junction; E shows the ureter (ur) as it approaches the wall of the
bladder (bl), and F is a serial section showing patency of the ureterovesical
junction (magnified in inset). Images are representative of two experiments,
total n=10 mice per condition.
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CRO treatment
We adapted CRO treatment regimens reported previously in female murine
models to clear UTI and to provide circulating drug levels similar to those
seen in patients treated with CRO (Lepeule et al., 2012; Tratselas et al.,
2014). At 120 h after surgical infection, male C3H/HeN mice received
125 mg kg−1 CRO dissolved in sterile water by subcutaneous injection;
mock-treated animals received an equivalent volume of PBS. Mice received
similar subcutaneous injections of CRO or PBS every 12 h for 5 days (i.e.
ten doses in total). Bladders and kidneys were aseptically harvested 24 h
after the last treatment to allow for clearance of residual CRO from the
tissues (see Fig. 1A).
Determination of urine and tissue bacterial loads
Where indicated, we noninvasively obtained post-infection clean-catch
urine samples using gentle suprapubic pressure for serial dilution and
plating to enumerate CFU ml−1 urine. At the indicated time points, mice
were euthanized via CO2 asphyxiation, and bladders and kidney pairs were
aseptically removed and homogenized in 1 ml or 0.8 ml sterile PBS,
respectively. We plated serial dilutions of tissue homogenates on LB agar to
enumerate bacterial loads. Where indicated, infection in C3H/HeNmicewas
classified as ‘chronic’ if all urine and endpoint bladder titers contained
>104 CFU ml−1, whereas ‘resolved’ mice demonstrated endpoint bladder
burdens and at least one urine time point with <104 CFU ml−1 (Hannan
et al., 2010).
Blood and urine chemistries
Serum or urine was analyzed on the day of collection for BUN, serum
creatinine or urine protein by standard autoanalyzer laboratory methods
performed by the Department of ComparativeMedicine veterinary facility at
Washington University.
Tissue histopathology
Infected bladders and kidneys were bisected and fixed in 10% neutral
buffered formalin for 24 h. Fixed tissues were embedded in paraffin,
sectioned, and stained with hematoxylin and eosin or Gomori trichrome
stain before light microscopy. Whole-kidney images (Fig. 7B,C) were
acquired with the AxioScan Z1 Automated Slide Scanning System and
digitally tiled by the acquisition software.
Statistical analysis
Statistics and graphing were performed using Prism 7 (GraphPad Software,
La Jolla, CA). Organ bacterial loads and other numerical data were
compared by the nonparametric Mann–Whitney U-test. 2×2 comparisons
were analyzed using the Fisher exact test. P-values <0.05 were considered
significant.
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Supplementary Figure S1.  Antibiotic treatment begun 2 weeks post infection (wpi) fails to 
sterilize the urinary tract.  Male C3H/HeN mice were infected with UTI89 as described in 
Materials and Methods.  Beginning 2 wpi, mice received ceftriaxone 125 mg/kg SQ every 12 h 
for 5 d (A) or an equivalent volume of PBS (B).  Shown for each condition are urine bacterial 
loads (colony-forming units [CFU]/mL) prior to the start of treatment (2 wpi) and at the 
conclusion of treatment, and the bacterial loads (CFU/organ) in bladders and kidneys upon 
sacrifice 20 dpi.  A solid line connects the data points for each individual mouse.   
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Supplementary Figure S2.  Ceftriaxone dosing every 6 h yields microbiologic cure similar 
to the twice-daily regimen.  C3H/HeN male mice were infected with UTI89 as described in 
Materials and Methods, and ceftriaxone 70 mg/kg SQ every 6 h was commenced 5 dpi.  Shown 
are urine titers (colony-forming units [CFU]/mL) pre-treatment (5 dpi) and at 6 and 7 dpi, as well 
as bladder and kidney bacterial loads (CFU/organ) at sacrifice 11 dpi.  A solid line connects the 
data points for each individual mouse. 
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Supplementary Figure S3.  Ceftriaxone treatment rapidly sterilizes urine cultures.  Shown 
are bacterial loads (colony-forming units [CFU]/mL) in urine cultures at the indicated time 
points in UPEC-infected C3H male mice receiving a 5-day course of ceftriaxone (CRO; red) or 
control (PBS; black) beginning 5 dpi.  A solid line connects the data points for each individual 
mouse.   
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